ChromaDex Corp. (NASDAQ:CDXC) announced today that it entered into a strategic supply agreement for Niagen® with Ro, a healthcare-technology company. The agreement provides Ro with rights to ChromaDex’s patented nicotinamide riboside ingredient Niagen®, the sole active ingredient in Tru Niagen®, for specially formulated Roman products.

Read more here.

Coinsmart. Beste Bitcoin-Börse in Europa
Source: https://blog.ourcrowd.com/chromadex-and-ro-partner-for-new-product-development/